ASTRO research demonstrates high-risk prostate cancer management with PSMA PET/CT

mg4155mg娱乐网址|诚信TOP!!

<acronym id="jy8ej"><strong id="jy8ej"></strong></acronym>
<acronym id="jy8ej"><strong id="jy8ej"><listing id="jy8ej"></listing></strong></acronym>
  • <p id="jy8ej"></p>
    <table id="jy8ej"></table><pre id="jy8ej"><label id="jy8ej"><menu id="jy8ej"></menu></label></pre>
      <pre id="jy8ej"></pre>

        1. Auction Alert - Premier Medical Depot - Closing Dec 2nd - Bid on Over 365 Lots

          ASTRO research demonstrates high-risk prostate cancer management with PSMA PET/CT

          by John R. Fischer, Senior Reporter | October 28, 2020
          Molecular Imaging Rad Oncology
          PSMA PET/CT has greater sensitivity and specificity than conventional imaging for detecting and accurately staging disease status for high-risk prostate cancer
          Researchers at the 2020 ASTRO virtual Annual Meeting are touting a new study that demonstrates the ability of PSMA PET/CT to distinguish between localized and metastatic cases of high-risk prostate cancer.

          Staging of the disease is currently done with the use of a CT scan, usually of the abdomen and pelvis, and a technetium bone scan. The authors say the findings of their post hoc analysis show the effective role that PSMA PET/CT plays in the management of high-risk prostate cancer. The title of the study is Impact of 68Ga-PSMA-11 PET/CT on Initial Staging of High-Risk Prostate Cancer Patients: Post-Hoc Analysis of a Prospective Single Center Experience on the staging impact of PSMA PET/CT in men with NCCN high-risk prostate cancer.

          “Conventional imaging for initial staging of prostate cancer (PCa) lacks sensitivity and underestimates disease burden,” said the authors in their study. “Prostate-specific membrane antigen PET/CT (PSMA PET) is an emerging imaging modality shown to have improved sensitivity over conventional imaging in the setting of biochemical recurrence.”

          Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

          Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

          The study evaluated 249 patients with NCCN high/very high risk PCa who underwent PSMA PET imaging in a prospective trial between December 2016 and January 2020. PSMA PET upstaged 22.9% of patients, with 18.9% who were diagnosed with iN0 disease by CT or MR found to have N1 disease, and 10.6% given an M0 disease status by CT or bone scan now given an M1 disease status. Meanwhile, 7.4% received a new M1a disease and 5.3% were found to have M1b/M1c disease. In addition, PSMA PET detected ECE (the local spread of cancer beyond the prostate), seminal vesicle invasion or invasion of surrounding structures in 8.1% of patients ranked as T2 on prior MR imaging.

          Those with a grade group of five or percentage of positive biopsy cores (PPC)≥50% were more likely to have regional nodal upstage and any upstage in general, while patients with GG 5 together with ≥50% PPC were predicted to have M stage upstage. cT and iPSA were not associated with upstaging.

          While increasing in availability worldwide due to its higher sensitivity and specificity over conventional imaging, PSMA PET/CT is still limited in use, including in the U.S. where the FDA has not yet approved the agent.

          Overall, PSMA PET/CT identified 19.7% of patients with regional PET positive nodal disease and 9.4% with metastatic disease on PET/CT. While not uniformly biopsy-proven areas for metastatic disease, it is possible based on prior research that 85%-98% of lesions found in these areas are likely to be prostate cancer, according to Dr. Daniel Spratt, a radiation oncologist at the University of Michigan who saw the presentation. He adds that the findings show that GG 5 (Gleason Score of 9-10) and >50% of biopsy cores involved with cancer predicted for non-localized prostate cancer.

          “Based on clinical trials led out of UCLA, UCSF and other centers, I am hopeful that these molecular imaging modalities can soon be added to our toolbox to better personalize our treatments,” wrote Spratt in an ASTRO op-ed.

          The findings were published in the International Journal of Radiation Oncology · Biology · Physics.

          You Must Be Logged In To Post A Comment

          mg4155mg娱乐网址